Age, sex, and APOE genotype have previously been shown to affect rates of tau accumulation and cognitive performance across the AD clinical spectrum.50,51,52 In the present study, we examined whether age, sex, and APOE genotype act as modifiers of the association between baseline tau PET and cognitive change over time. Here, MAPT is linked to Alzheimer disease.